Related Experiment Video
Updated: Jun 3, 2026
07:43
Modeling Charcot-Marie-Tooth Disease In Vitro by Transfecting Mouse Primary Motoneurons
Published on: January 7, 2019
ALS, what new 144 years after Charcot?
1Centre Référent Maladies Rares, APHP, UPMC, Hôpital de la Salpêtrière, Paris France. vincent.meininger@psl.aphp.fr
Archives Italiennes De Biologie
|March 18, 2011
Summary
Finding reliable biomarkers for Amyotrophic Lateral Sclerosis (ALS) is crucial. While clinical assessment is key, emerging -omics technologies offer new hope for discovering sensitive and specific diagnostic markers beyond current methods.
Area of Science:
- Neurology
- Biomarker Discovery
- Molecular Biology
Background:
- Accurate biomarkers for Amyotrophic Lateral Sclerosis (ALS) are essential for diagnosis and patient management.
- Current diagnostic methods rely heavily on clinical assessment, with neurophysiology showing limited utility in clinical trials.
- Neuroimaging offers insights into upper motor neuron integrity, but lacks specificity for ALS progression.
Discussion:
- Nogo levels in muscle biopsies represent a promising protein marker for ALS.
- Cerebrospinal fluid (CSF) protein candidates have shown disappointing sensitivity and specificity.
- Advanced -omics technologies, including genomics, proteomics, and metabolomics, are being explored for novel ALS biomarker identification.
Key Insights:
- The search for effective ALS biomarkers remains a significant clinical challenge.
- Muscle biopsy Nogo levels show potential as a diagnostic marker.
- -omics approaches are vital for uncovering new molecular targets in ALS.
Outlook:
- Future research will focus on validating -omics-derived biomarkers for clinical application in ALS.
- Integrating multi-omics data may improve diagnostic accuracy and treatment monitoring.
- Development of sensitive and specific biomarkers is critical for advancing ALS therapeutics.
